Spero Therapeutics Financials - Benzinga

Spero Therapeutics Inc

SPRONASDAQ

Trade with Public

Trade with Public

$1.23

0.0151.23%

At close: Aug 25, 5:00 PM EST

$1.23

N/A

After Hours: 8:51 AM EST

Overview News Earnings Forecast Events Price TargetsFinancialsSentiment Ownership Compare Options Stock Report

Spero Therapeutics Financials

Spero Therapeutics (SPRO) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Spero Therapeutics Q2 EPS $(0.16) Down From $(0.03) YoY

Benzinga Newsdesk

PRO
Spero Therapeutics Q1 EPS $(0.13) Beats $(0.18) Estimate, Sales $258.000K Down From $5.874M YoY

Spero Therapeutics (NASDAQ:SPRO) reported quarterly losses of $(0.13) per share which beat the analyst consensus estimate of $(0.18) by 27.78 percent. This is a 48 percent increase over losses of $(0.25) per share from

Benzinga Newsdesk

Earnings Scheduled For May 13, 2026

Benzinga Insights

PRO
Spero Therapeutics Q4 EPS $0.53 Beats $(0.40) Estimate, Sales $41.297M Up From $15.044M YoY

Spero Therapeutics (NASDAQ:SPRO) reported quarterly earnings of $0.53 per share which beat the analyst consensus estimate of $(0.40) by 232.5 percent. This is a 239.47 percent increase over losses of $(0.38) per share

Benzinga Newsdesk

Earnings Scheduled For March 26, 2026

Benzinga Insights

PRO
Spero Therapeutics Q3 EPS $(0.13) Beats $(0.39) Estimate, Sales $5.442M Down From $13.469M YoY

Benzinga Newsdesk